

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/AAFDD1F49ACEN.html>

Date: December 2019

Pages: 76

Price: US\$ 3,500.00 (Single User License)

ID: AAFDD1F49ACEN

Abstracts

Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019

SUMMARY

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediate a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 2, 4, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules respectively.

Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Ophthalmology, Genito Urinary System And Sex Hormones, Male Health, Central Nervous System, Musculoskeletal Disorders, Oncology, Respiratory and

Women's Health which include indications Glaucoma, Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Kidney Fibrosis, Arthritis, Chemotherapy Induced Pain, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammation, Male Sexual Dysfunction, Melanoma, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Adenosine Receptor A3 (ADORA3) - Overview

Adenosine Receptor A3 (ADORA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development

Acorn Biomedical Inc

BioIntervene Inc

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL

Adenosine Receptor A3 (ADORA3) - Drug Profiles

ACN-1052 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namodenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease -
Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones

Featured News & Press Releases

Dec 09, 2019: Can-Fite completes 50% patient enrollment in its phase III Psoriasis Trial

Dec 05, 2019: Can-Fite to attend BioFIT 2019 Conference in Europe with focus on partnering meetings for Namodenoson in NASH

Nov 19, 2019: Can-Fite granted patents for its sexual dysfunction drug

Nov 11, 2019: Can-Fite granted U.S. Patent for piclidenoson in the treatment of osteoarthritis, positioning this indication for animal health market

Nov 04, 2019: Can-Fite initiates compassionate use program for namodenoson in the treatment of liver cancer, enrolls and treats patients

Oct 31, 2019: U.S. FDA agreed with Can-Fite's proposed pivotal phase III trial design to support a new drug application submission and approval of Namodenoson in the treatment of Liver Cancer

Oct 17, 2019: Can-Fite and Gebro Pharma holding European Conference on development & commercialization of phase III drug candidate Piclidenoson in the treatment of Rheumatoid Arthritis

Oct 15, 2019: Can-Fite completes patient enrollment in phase II NASH study of Namodenoson

Oct 10, 2019: Can Fite announces publication of Namodenoson NASH mechanism of action in International Journal of Molecular Medicine

Sep 23, 2019: Can-Fite presents new data on the treatment of advanced liver cancer with Namodenoson at the ILCA Conference

Sep 23, 2019: Can-Fite presents new data on the treatment of advanced liver cancer with Namodenoson at the ILCA Conference

Aug 06, 2019: Can-Fite to treat Advanced Liver Cancer patients with Namodenoson under compassionate use setting in Israel

Jun 04, 2019: Can-Fite Participating in One-on-One Partnering Meeting for Piclidenoson at the BIO International Convention on June 3-6, 2019

Jun 04, 2019: Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019

Jun 03, 2019: Findings from Can-Fites phase II Liver Cancer Study were presented at ASCO Annual Meeting Late-Breaking Session

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Acorn Biomedical Inc, H2 2019
Pipeline by BioIntervene Inc, H2 2019
Pipeline by Can-Fite BioPharma Ltd, H2 2019
Pipeline by Future Medicine Co Ltd, H2 2019
Pipeline by Palo BioFarma SL, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

COMPANIES MENTIONED

Acorn Biomedical Inc

BioIntervene Inc

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL

I would like to order

Product name: Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/AAFDD1F49ACEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AAFDD1F49ACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970